Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.05m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Directorate Change

29 Nov 2018 10:37

RNS Number : 9093I
Maven Income & Growth VCT PLC
29 November 2018
Β 

Maven Income and Growth VCT PLC (the Company)

Β 

Directorate Changes

Β 

As announced on 26 September 2018, alongside the publication of the Prospectus for the Offer for Subscription, the Board now confirms that Fiona Wollocombe will resign as a Non-executive Director of the Company with effect from 24 January 2019. Mrs Wollocombe has been a Director of the Company since 20 May 2004, serving as its Chairman from 7 July 2005 until 8 July 2010, and the Board wishes to record its gratitude for the significant contribution Fiona made during her time in office and extends to her its best wishes for the future.

Β 

The Board is also pleased to announce the appointments of Dr Alison Fielding and Dr Andrew Harrington as Non-executive Directors, each with effect from 1 January 2019. Both of these new Directors will also serve on the Company's Audit, Management Engagement, Nomination, Risk and Remuneration Committees, and will stand for election by Shareholders at the Annual General Meeting to be held in July 2019

Β 

Dr Fielding is an experienced entrepreneur, senior executive and non-executive director, with a track record of leading strategy within both large and small organisations to set direction, evaluate options, implement plans and drive performance. She is currently a venture partner at IP Group plc, with her role there including two non-executive directorships with portfolio companies; Perachem Holdings plc, of which she is chairman, and Getech Group plc, where she chairs the audit committee.

Β 

Alison has held a number of other non-executive roles and her other current appointments include non-executive directorships of Nanoco Group plc and Queen Mary Innovation Limited, and serving as a trustee of the Royal Voluntary Service and the Carnegie Trust for the Universities of Scotland.

Β 

Dr Harrington is co-owner of AHV Associates LLP, which was formed in 2001 and works alongside management teams and shareholders across many sectors to advise on transactions, such as the purchase or sale of companies and capital raising.

Β 

Andrew was previously founder and chief executive of Nextcall Telecom, a business backed by venture and private investor capital, before which he was managing director at Salomon Brothers, where he advised on investment, IPOs, secondary public market offerings and mergers & acquisitions.

Β 

In relation to both of these new appointments, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

Β 

Maven Capital Partners UK LLP

Secretary

29 November 2018

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
BOAPGGQWGUPRGUB
Date   Source Headline
20th Apr 20214:56 pmRNSTransaction in Own Shares
16th Apr 20214:40 pmRNSNet Asset Value and Proposed Final Dividend
6th Apr 202112:50 pmRNSDirector/PDMR Shareholding
6th Apr 20217:00 amRNSIssue of Equity
24th Mar 20215:56 pmRNSStatement re Offer for Subscription
23rd Mar 20213:41 pmRNSPublication of Suppl.Prospcts
3rd Mar 20217:05 amRNSDirector/PDMR Shareholding
3rd Mar 20217:00 amRNSIssue of Equity
8th Feb 20219:56 amRNSStatement re Offer for Subscription
4th Feb 20215:10 pmRNSTransaction in Own Shares
29th Jan 20214:42 pmRNSTransaction in Own Shares
28th Jan 20214:40 pmRNSStatement re Offer for Subscription
22nd Jan 20213:13 pmRNSNet Asset Value(s)
27th Nov 202010:41 amRNSResult of General Meeting
20th Nov 20205:18 pmRNSIssue of Equity
16th Nov 20204:53 pmRNSTransaction in Own Shares
13th Nov 20203:43 pmRNSStatement re Dividend Investment Scheme
26th Oct 20207:00 amRNSPublication of a Prospectus
19th Oct 20204:43 pmRNSHalf-year Report
15th Oct 20204:45 pmRNSStatement re NAV and Interim Dividend
26th Aug 20205:19 pmRNSTransaction in Own Shares
29th Jul 20204:42 pmRNSTransaction in Own Shares
28th Jul 20204:48 pmRNSTransaction in Own Shares
22nd Jul 20203:12 pmRNSNet Asset Value(s)
22nd Jul 20202:25 pmRNSStatement re Intended Joint Offersfor Subscription
22nd Jul 202012:18 pmRNSResult of AGM
29th May 202011:37 amRNSAnnual Financial Report
26th May 20204:54 pmRNSTransaction in Own Shares
27th Apr 20204:19 pmRNSTransaction in Own Shares
21st Apr 20205:17 pmRNSNet Asset Value & Final Dividend
26th Mar 20205:25 pmRNSUpdate on Net Asset Value
26th Mar 20205:00 pmRNSSuspension of Dividend Investment Scheme
19th Mar 20201:48 pmRNSDirector Declaration
23rd Jan 20203:36 pmRNSNet Asset Value(s)
4th Dec 20199:45 amRNSStatement re Share Premium Account Cancellation
28th Nov 20195:06 pmRNSTransaction in Own Shares
22nd Nov 20193:31 pmRNSDirector/PDMR Shareholding
22nd Nov 20192:45 pmRNSIssue of Equity
20th Nov 20194:44 pmRNSStatement re Dividend Investment Scheme
31st Oct 20194:42 pmRNSHalf-year Report
15th Oct 20192:33 pmRNSTransaction in Own Shares
15th Oct 20199:56 amRNSStatement re Net Asset Value and Interim Dividend
31st Jul 20193:37 pmRNSTransaction in Own Shares
4th Jul 20191:08 pmRNSNet Asset Value(s)
4th Jul 201912:55 pmRNSResult of AGM
24th May 20193:09 pmRNSAnnual Financial Report
20th May 20194:34 pmRNSTransaction in Own Shares
20th May 201911:29 amRNSTransaction in Own Shares
24th Apr 20199:47 amRNSIssue of Equity
5th Apr 20194:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.